US › Healthcare

CAMP4 THERAPEUTICS CORPORATION (CAMP)

US · Healthcare · Biotechnology

$4.03+4.40%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$1.8M

Revenue YoY

+18.8%

Net profit

$-33.5M

EPS

$-0.22

EPS estimate

$-0.24

Net margin

-1,884.8%

EPS came in at -0.22 against a street estimate of -0.24 — a beat of 8.3%.

Key statistics

Market cap

$266.7M

Forward P/E

0.0

P/B

9.11

Book value

$-0.01

EPS (TTM)

$-2.31

52-week high

$7.75

52-week low

$2.20

50-day MA

$4.12

200-day MA

$4.50

Analyst view

Analysts rate CAMP4 THERAPEUTICS CORPORATION a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $9.92.

Shareholding

Insiders

9.65%

Institutions

79.69%

Largest institutional holders

Fund	Stake
HHG PLC	10.05%
5AM Venture Management, LLC	9.35%
FMR Inc	7.86%
Vivo Capital, LLC	6.77%
Balyasny Asset Management LLC	4.19%
Adage Capital Partners Gp LLC	3.12%
Trails Edge Capital Partners, LP	3.08%
Vanguard Capital Management, LLC	2.45%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for CAMP4 THERAPEUTICS CORPORATION — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.